SRZN Surrozen
- 10.1525
- -0.2970-2.84%
Surrozen News
Surrozen Presents Data Demonstrating The Promise Of Antibody-Based Wnt Mimetics In Treating Cornea Endothelial Dystrophies And Dry Eye Disease At The ARVO Annual Meeting
In preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema and stimulated endothelial cell proliferation in the corneaSurrozen's antibody base
Surrozen Q1 EPS $(4.24) Beats $(4.25) Estimate
Surrozen (NASDAQ:SRZN) reported quarterly losses of $(4.24) per share which beat the analyst consensus estimate of $(4.25) by 0.24 percent. This is a 41.11 percent increase over losses of $(7.20) per
10-Q: Quarterly report
Surrozen Provides First Quarter 2024 Financial Results and Business Update
SZN-043 Phase 1a clinical trial results to be presented at the 2024 European Association for the Study of the Liver (EASL) in Milan.
Surrozen Files to Sell 1.09M Shares of Common Stock for Holders
RA Capital Management Reports 9.99% Passive Stake In Surrozen As Of April 4 In 13G Filing
RA Capital Management Reports 9.99% Passive Stake In Surrozen As Of April 4 In 13G Filing
Patent Battles: Surrozen, Inc. at Risk of Financial Instability Amid IP Challenges
Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM)
Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing
Tim Kutzkey, 10% Owner, Director, on April 04, 2024, executed a purchase for 193,548 shares in Surrozen (SRZN) for $2,999,994. Following the Form 4 filing with the SEC, Kutzkey has control over a tota
Surrozen Publishes Study In 'Respiratory Research' Highlighting Surrozen's Wnt Mimetic Technologies In Treating Pulmonary Fibrosis
Surrozen Publishes Study In 'Respiratory Research' Highlighting Surrozen's Wnt Mimetic Technologies In Treating Pulmonary Fibrosis
Surrozen Shares Tumble 26% on Securities Purchase Agreement
By Denny Jacob Surrozen shares tumbled 26% to $11.60 following a securities purchase agreement with certain investors. The stock is up 28% over the last 12 months. The clinical stage biotechnology
Surrozen Highlights SZN-043 Data on Safety and Liver Function
Surrozen Announces Safety, Pharmacodynamic And Liver Function Data For SZN-043; Says Phase 1A Trial Demonstrated 'Acceptable' Safety And Tolerability With No Reported Serious Adverse Events
Surrozen Announces Safety, Pharmacodynamic And Liver Function Data For SZN-043; Says Phase 1A Trial Demonstrated 'Acceptable' Safety And Tolerability With No Reported Serious Adverse Events
Surrozen Announces Up to $192.5M Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
Surrozen Announces Up to $192.5M Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
Surrozen Promotes Charles Williams to COO With CFO Role
Sector Update: Health Care Stocks Weaker Thursday Afternoon
Health care stocks fell Thursday afternoon, with the NYSE Health Care Index declining 0.8% and the Health Care Select Sector SPDR Fund (XLV) down 0.7%. The iShares Biotechnology ETF (IBB) fell 1%. In
Surrozen to Stop Inflammatory Bowel Disease Clinical Trial; Shares Fall
Surrozen (SRZN) said Thursday it has decided to stop the development of SZN-1326 in inflammatory bowel disease due to dosing issues, significant development expenses, and market competition. The compa
We're Keeping An Eye On Surrozen's (NASDAQ:SRZN) Cash Burn Rate
Surrozen Shares To Resume Trading At 09:00 A.m ET
Surrozen Shares To Resume Trading At 09:00 A.m ET
Surrozen To Carry Out 1-for-15 Reverse Stock Split On December 14th, 2023
December 13th - $Surrozen(SRZN.US)$ is about to implement a 1-for-15 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from December 14th, 2023.$Surrozen(SRZN.US)$
Analysis
Price Target
No Data
